Xingze Capital
杏泽资本
Xingze Capital (杏泽资本) is a venture capital fund that appears in elsewhere's corpus primarily as a co-investor in biotech deals — most recently, it followed on in Zhitai Bio's Series C round alongside Qiming Venture Partners, 5Y Capital, and Huagai Capital . The retrieved material does not include dedicated coverage of Xingze's own founding, team, or strategy; elsewhere's corpus does not cover this subject in depth.
AI-generated — may contain errors, please verify.
Xingze CapitalFund
杏泽资本
渲染中…
Mentioned in 3 articles
Coverage
5Y News｜Aikelian Biotechnology Completes $68.7 Million Funding Round
Aikelian Biotech has successfully completed an oversubscribed $68.7 million funding round.
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
